Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, has reached an agreement to acquire CTI BioPharma, a US biopharma company focused on blood related cancers and rare diseases, by means of a tender offer.
The acquisition complements and further strengthens Sobi’s leading hematology franchise by adding Vonjo (pacritinib), a novel oral kinase inhibitor that inhibits JAK2, IRAK1 and ACRV1, while sparing JAK1. Vonjo obtained accelerated approval by the US Food and Drug Administration (FDA) in February 2022 for treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
Data and analytics company GlobalData has previously said that Vonjo’s ability to target such critically underserved and distinct patient populations means its annual sales are set to reach $235 million by 2027, despite upcoming market competition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze